AstraZeneca
Biopharmaceuticals · United Kingdom
AstraZeneca discovers, makes and sells prescription medicines for cancer, heart, lung and rare diseases, led by Farxiga, Tagrisso and Imfinzi.
What makes it different
Sixteen medicines each earn blockbuster sales.
16Blockbuster drugsFY2025
Revenue rests on many large products rather than a single drug.
How big it is
How big is AstraZeneca?
$58.7BTotal RevenueFY2025
96,100EmployeesFY2025
$14.2BR&D expenseFY2025
How it makes money FY2025
Oncology and BioPharmaceuticals make up most of revenue.
- Oncology44%$25.6B
- BioPharmaceuticals39%$23.0B
- Rare Disease16%$9.1B
- Other medicines2%$999M
How the business works
Invest in science, lead three areas, sell worldwide.
- 1New molecules and technologies
- 2Oncology, BioPharma, rare disease
- 3Global network incl. emerging markets
Growth rests on many large medicines, so new launches must replace those facing generics such as Farxiga.
Who owns it
- BlackRock, Inc.6.5%
- The Capital Group Companies, Inc.4.97%
- Wellington Management Group LLP4.2%
CEO: Pascal Soriot
Who it competes with
Key moments
- 1993Zeneca formed in demerger from ICI
- 4-06Merges with Astra of Sweden
- 2000Agrochemicals merged into Syngenta
- 2007Acquires MedImmune
- 0-01Pascal Soriot joins as CEO
Sources
Every number on this page comes from AstraZeneca's own reports.
Full profile
The rest of the story is in the app.
What AstraZeneca tracks25 metrics
Phase III studies ongoing
People positively impacted
Employees
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from4 regions
United States
Emerging Markets
Europe
The full timeline16 moments
2019
2025
2026
AstraZeneca vs Novartisside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
